Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
Authors
Keywords
Antibody response, Vaccines, Routes of administration, Influenza, Antibodies, Vaccination and immunization, DNA vaccination, Elderly
Journal
PLoS One
Volume 14, Issue 9, Pages e0222178
Publisher
Public Library of Science (PLoS)
Online
2019-09-19
DOI
10.1371/journal.pone.0222178
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
- (2018) Martin R Gaudinski et al. LANCET
- DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial
- (2018) Katherine V. Houser et al. PLoS One
- A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control
- (2017) Riju Ray et al. Human Vaccines & Immunotherapeutics
- An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
- (2017) Adam D. DeZure et al. npj Vaccines
- 2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type
- (2016) Richard K. Zimmerman et al. CLINICAL INFECTIOUS DISEASES
- Influenza Vaccines: Challenges and Solutions
- (2015) Katherine Houser et al. Cell Host & Microbe
- Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost
- (2015) Julie E. Ledgerwood et al. Contemporary Clinical Trials
- Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
- (2015) Michelle C. Crank et al. PLoS One
- DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial
- (2015) Julie E. Ledgerwood et al. PLoS One
- Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States
- (2015) Carrie Reed et al. PLoS One
- DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases
- (2014) Julie E. Ledgerwood et al. Human vaccines & immunotherapeutics
- Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
- (2014) Carlos A. DiazGranados et al. NEW ENGLAND JOURNAL OF MEDICINE
- Seasonal influenza vaccine dose distribution in 157 countries (2004–2011)
- (2014) Abraham Palache et al. VACCINE
- Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect
- (2013) Julie E. Ledgerwood, Kathryn Zephir, Zonghui Hu, Chih-Jen Wei, LeeJah Chang, Mary E. Enama, Cynthia S. Hendel, Sandra Sitar, Robert T. Bailer, Richard A. Koup, John R. Mascola, Gary J. Nabel, Barney S. Graham et al. JOURNAL OF INFECTIOUS DISEASES
- Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18–64 years of age
- (2013) Geoffrey J. Gorse et al. VACCINE
- Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age
- (2013) Geoffrey J. Gorse et al. VACCINE
- Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial
- (2013) Peter Tsang et al. VACCINE
- Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans
- (2012) J. E. Ledgerwood et al. Clinical and Vaccine Immunology
- Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch
- (2012) Yeu-Chun Kim et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- A Meta-analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events
- (2012) Fawziah Marra et al. Influenza and Other Respiratory Viruses
- DNA Vaccination in the Skin Using Microneedles Improves Protection Against Influenza
- (2012) Jae-Min Song et al. MOLECULAR THERAPY
- DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
- (2011) Julie E Ledgerwood et al. LANCET INFECTIOUS DISEASES
- Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
- (2011) Michael T Osterholm et al. LANCET INFECTIOUS DISEASES
- A systematic review of intradermal influenza vaccines
- (2011) Flora Young et al. VACCINE
- Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults
- (2011) Robert W. Frenck et al. VACCINE
- Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
- (2009) Ann R. Falsey et al. JOURNAL OF INFECTIOUS DISEASES
- Better Influenza Vaccines for Older People: What Will It Take?
- (2008) Janet E. McElhaney et al. JOURNAL OF INFECTIOUS DISEASES
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
- (2008) Julie E. Martin et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now